Literature DB >> 9819429

The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.

N Adya1, T Stacy, N A Speck, P P Liu.   

Abstract

The fusion gene CBFB-MYH11 is generated by the chromosome 16 inversion associated with acute myeloid leukemias. This gene encodes a chimeric protein involving the core binding factor beta (CBFbeta) and the smooth-muscle myosin heavy chain (SMMHC). Mouse model studies suggest that this chimeric protein CBFbeta-SMMHC dominantly suppresses the function of CBF, a heterodimeric transcription factor composed of DNA binding subunits (CBFalpha1 to 3) and a non-DNA binding subunit (CBFbeta). This dominant suppression results in the blockage of hematopoiesis in mice and presumably contributes to leukemogenesis. We used transient-transfection assays, in combination with immunofluorescence and green fluorescent protein-tagged proteins, to monitor subcellular localization of CBFbeta-SMMHC, CBFbeta, and CBFalpha2 (also known as AML1 or PEBP2alphaB). When expressed individually, CBFalpha2 was located in the nuclei of transfected cells, whereas CBFbeta was distributed throughout the cell. On the other hand, CBFbeta-SMMHC formed filament-like structures that colocalized with actin filaments. Upon cotransfection, CBFalpha2 was able to drive localization of CBFbeta into the nucleus in a dose-dependent manner. In contrast, CBFalpha2 colocalized with CBFbeta-SMMHC along the filaments instead of localizing to the nucleus. Deletion of the CBFalpha-interacting domain within CBFbeta-SMMHC abolished this CBFalpha2 sequestration, whereas truncation of the C-terminal-end SMMHC domain led to nuclear localization of CBFbeta-SMMHC when coexpressed with CBFalpha2. CBFalpha2 sequestration by CBFbeta-SMMHC was further confirmed in vivo in a knock-in mouse model. These observations suggest that CBFbeta-SMMHC plays a dominant negative role by sequestering CBFalpha2 into cytoskeletal filaments and aggregates, thereby disrupting CBFalpha2-mediated regulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819429      PMCID: PMC109324          DOI: 10.1128/MCB.18.12.7432

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells.

Authors:  W Cao; M Britos-Bray; D F Claxton; C A Kelley; N A Speck; P P Liu; A D Friedman
Journal:  Oncogene       Date:  1997-09       Impact factor: 9.867

2.  Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.

Authors:  S Mundlos; F Otto; C Mundlos; J B Mulliken; A S Aylsworth; S Albright; D Lindhout; W G Cole; W Henn; J H Knoll; M J Owen; R Mertelsmann; B U Zabel; B R Olsen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

3.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

4.  Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.

Authors:  P Ducy; R Zhang; V Geoffroy; A L Ridall; G Karsenty
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.

Authors:  F Otto; A P Thornell; T Crompton; A Denzel; K C Gilmour; I R Rosewell; G W Stamp; R S Beddington; S Mundlos; B R Olsen; P B Selby; M J Owen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

6.  The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo.

Authors:  Q Wang; T Stacy; J D Miller; A F Lewis; T L Gu; X Huang; J H Bushweller; J C Bories; F W Alt; G Ryan; P P Liu; A Wynshaw-Boris; M Binder; M Marín-Padilla; A H Sharpe; N A Speck
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

7.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.

Authors:  K Sasaki; H Yagi; R T Bronson; K Tominaga; T Matsunashi; K Deguchi; Y Tani; T Kishimoto; T Komori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

8.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

Authors:  D A Yergeau; C J Hetherington; Q Wang; P Zhang; A H Sharpe; M Binder; M Marín-Padilla; D G Tenen; N A Speck; D E Zhang
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

9.  The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures.

Authors:  Y Tanaka; T Watanabe; N Chiba; M Niki; Y Kuroiwa; T Nishihira; S Satomi; Y Ito; M Satake
Journal:  Oncogene       Date:  1997-08-07       Impact factor: 9.867

10.  Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.

Authors:  P P Liu; C Wijmenga; A Hajra; T B Blake; C A Kelley; R S Adelstein; A Bagg; J Rector; J Cotelingam; C L Willman; F S Collins
Journal:  Genes Chromosomes Cancer       Date:  1996-06       Impact factor: 5.006

View more
  38 in total

1.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

3.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

Review 5.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

6.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 7.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

8.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

9.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.

Authors:  R Katherine Hyde; Yasuhiko Kamikubo; Stacie Anderson; Martha Kirby; Lemlem Alemu; Ling Zhao; P Paul Liu
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

10.  The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis.

Authors:  Yasuhiko Kamikubo; R Katherine Hyde; Ling Zhao; Lemlem Alemu; Cecilia Rivas; Lisa J Garrett; P Paul Liu
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.